Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Atara Biotherapeutics (ATRA) Asset Writedowns and Impairment (2025)

Atara Biotherapeutics filings provide 1 years of Asset Writedowns and Impairment readings, the most recent being $4.1 million for Q1 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $4.1 million in Q1 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a N/A change, with the full-year FY2025 number at $4.1 million, changed N/A from a year prior.
Asset Writedowns and Impairment hit $4.1 million in Q1 2025 for Atara Biotherapeutics.
In the past five years, Asset Writedowns and Impairment ranged from a high of $4.1 million in Q1 2025 to a low of $4.1 million in Q1 2025.